

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
14 February 2002 (14.02.2002)

PCT

(10) International Publication Number
WO 02/11766 A2(51) International Patent Classification⁷: A61K 45/08,
A61P 9/06

(21) International Application Number: PCT/GB01/03544

(22) International Filing Date: 7 August 2001 (07.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0019410.0	7 August 2000 (07.08.2000)	GB
0019523.0	8 August 2000 (08.08.2000)	GB
0019524.8	8 August 2000 (08.08.2000)	GB
0118919.0	2 August 2001 (02.08.2001)	GB
0119022.2	3 August 2001 (03.08.2001)	GB

(71) Applicants (for all designated States except US): **LABORATOIRE GLAXOSMITHKLINE S.A.S.** [FR/FR]; 100 route de Versailles, F-78163 Marly-le-Roi Cedex (FR). **SMITHKLINE BEECHAM CORPORATION** [US/US]; One Franklin Plaza, P.O. Box 7929, Philadelphia, PA 19103 (US). **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BONHOMME, Mireille, Marguerite, Jeanne** [FR/FR]; Laboratoire GlaxoSmithKline S.A.S., Centre de recherches, 25, avenue du Québec, F-91951 Les Ulis (FR). **BRIL, Antoine, Michel, Alain** [FR/FR]; GlaxoSmithKline Pharmaceuticals, 709 Swedeland road, King of Prussia, PA 19406 (FR). **GOUT, Bernard, Emile, Joseph** [FR/FR]; Laboratoire GlaxoSmithKline S.A.S., Unité de Recherche, 4, rue du Chesnay-Beauregard, B.P. 96205, F-35760 Saint-Grégoire (FR). **PATEL, Bela, Rajiv** [US/US]; GlaxoSmithKline Pharmaceuticals, 709 Swedeland Road, King of Prussia, PA 19406 (US). **SHEPHERD, Gillian, Louise** [GB/GB]; Glaxo Wellcome plc, 891-995 Greenford Road, Greenford, Middlesex UB6 0HE (GB).

(74) Agent: **WATERS, David, Martin**; Corporate Intellectual Property, GlaxoSmithKline, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).



(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,

[Continued on next page]

(54) Title: THE USE OF 5HT₄ RECEPTOR ANTAGONISTS IN THE PROPHYLAXIS OR TREATMENT OF CERTAIN CARDIOVASCULAR CONDITIONS

5-HT₄ antagonists in atrial fibrillation / atrial remodelling / atrial pacing

- SB-207266 treated group (n=7)



(57) Abstract: The invention relates to the use of a 5-HT₄ receptor antagonist in the manufacture of a medicament for the prophylaxis or treatment of atrial remodelling in a mammal. Preferably, the antagonist is N-[(1ⁿ-butyl-4-piperidiny)l methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide (SB207266) or a pharmaceutically acceptable salt thereof. The invention also relates to the use of SB 207266 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of atrial fibrillation in a mammal by administering to the mammal a daily oral or parenteral dosage regimen of about 0.2 mg to 1.0 mg of the SB 207266 or salt thereof per kg of total body weight (measured as the free base). The invention also relates to the use of SB 207266 or a pharmaceutically acceptable salt thereof in the prophylaxis or treatment of atrial arrhythmia in a mammal by administration of the SB 207266 or salt thereof on the first day at a loading dose of about 1.2 to about 2.0 times the daily maintenance dose, followed by administration of the SB 207266 or salt at the daily maintenance dose on subsequent days.



MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.